{"cluster": 43, "subcluster": 20, "abstract_summ": "Patient concerns about the possible increased susceptibility to coronavirus disease 19 (COVID-19) infection or a more severe course of the disease when treated with immunosuppressive therapy may lead to lower treatment compliance.Recent studies have revealed that cytokine storm syndrome, which is caused by the activation of inflammatory cytokines, is a likely underlying pathophysiology in patients with severe COVID\u201019 that has been associated with a high mortality rate(1).Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far.We report herein a case series of patients with COVID\u201019 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes.", "title_summ": "Feasibility of Tocilizumab in ICU patients with COVID\u201019Off\u2010label Use of Tocilizumab in Patients with SARS\u2010CoV\u20102 InfectionUse of subcutaneous tocilizumab in patients with COVID\u201019 pneumoniaCOVID\u201019 pneumonia treated with Sarilumab: A clinical series of eight patientsPros and cons of corticosteroid therapy for COVID-19 patientsEfficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 casesShould SARS\u2010CoV\u20102 influence immunosuppressive therapy for autoimmune blistering diseases?Tocilizumab Administration in Patients with SARS\u2010CoV\u20102 Infection: Subcutaneous Injection versus Intravenous InfusionQTc evaluation in COVID\u201019 patients treated with chloroquine/hydroxychloroquineHandling of allergen immunotherapy in the COVID\u201019 pandemic: An ARIA\u2010EAACI statementCompliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic.Tocilizumab in the treatment of a critical COVID-19 patient: a case report.", "title_abstract_phrases": "Patient concerns about the possible increased susceptibility to coronavirus disease 19 (COVID-19) infection or a more severe course of the disease when treated with immunosuppressive therapy may lead to lower treatment compliance.Tocilizumab Administration in Patients with SARS\u2010CoV\u20102 Infection: Subcutaneous Injection versus Intravenous InfusionRecent studies have revealed that cytokine storm syndrome, which is caused by the activation of inflammatory cytokines, is a likely underlying pathophysiology in patients with severe COVID\u201019 that has been associated with a high mortality rate(1).Should SARS\u2010CoV\u20102 influence immunosuppressive therapy for autoimmune blistering diseases?In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID\u201019), scientific data relating to the causative virus SARS\u2010CoV\u20102 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.We report herein a case series of patients with COVID\u201019 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes.In this retrospective case series, all patients diagnosed with COVID\u201019 by semi quantitative RT\u2010PCR and hyperinflammatory markers were treated with tocilizumab."}